Core Viewpoint - Goldman Sachs has raised the earnings per share (EPS) forecasts for Innovent Biologics (01801) for 2025 to 2027, reflecting a positive outlook on the company's financial performance despite some challenges in the market [1] Financial Performance - The product revenue for Innovent Biologics in the fourth quarter of last year was approximately 3.3 billion RMB, meeting Goldman Sachs' expectations, with a year-on-year growth of 60% from a relatively low base, remaining flat quarter-on-quarter [1] - The company's new product portfolio continues to show growth, with a quarterly increase of 13%, which offsets the weak performance of Tyvyt [1] - For the full year of 2025, product sales are expected to be strong, with a projected year-on-year growth of 45% to 11.9 billion RMB, marking the first time sales exceed the 10 billion RMB milestone, driven primarily by the growth in the biopharmaceutical business [1] Target Price and Rating - The target price for Innovent Biologics has been adjusted to 102.85 HKD from the previous 107.96 HKD, while maintaining a "Buy" rating [1]

Core Viewpoint - Goldman Sachs has raised the earnings per share forecast for Innovent Biologics (01801) for 2025 to 2027, with target prices adjusted to HKD 102.85 from HKD 107.96, maintaining a "Buy" rating [1] Group 1: Earnings Forecast - The earnings per share estimates for Innovent Biologics have been increased to HKD 0.62, HKD 1.74, and HKD 2.54 for the years 2025, 2026, and 2027 respectively, up from HKD 0.54, HKD 1.43, and HKD 2.49 [1] - The company is expected to achieve a strong product sales performance in 2025, with a projected year-on-year growth of 45% to reach RMB 11.9 billion, marking a significant milestone of surpassing RMB 10 billion [1] Group 2: Revenue Performance - In the fourth quarter of the previous year, the product revenue was approximately RMB 3.3 billion, aligning with Goldman Sachs' expectations, and reflecting a year-on-year growth of 60% from a relatively low base, while remaining flat quarter-on-quarter [1] - The new product portfolio continues to show growth momentum, with a quarterly increase of 13%, which offsets the weak performance of Tyvyt [1]

Core Viewpoint - The competition for the title of "king of drugs" in the GLP-1 market is intensifying between Eli Lilly and Novo Nordisk, driven by the explosive growth of GLP-1 drugs globally [2][7]. Group 1: Financial Performance - Eli Lilly reported total revenue of $65.179 billion for the year 2025, a 44% increase year-over-year at constant exchange rates [2][3]. - The key driver of this growth was the GLP-1 drug tirzepatide, which contributed $36.5 billion in revenue (approximately 253.4 billion yuan) [2][4]. - Eli Lilly's fourth-quarter revenue reached $19.29 billion, a 43% year-over-year increase, with a net profit of $20.64 billion, up 95% [3][4]. Group 2: Market Dynamics - The GLP-1 market is currently dominated by Eli Lilly and Novo Nordisk, with combined revenues approaching $50 billion in 2024 [7]. - Eli Lilly's tirzepatide is positioned to capture both diabetes and obesity markets, with Zepbound showing a significant sales growth of 175% in the obesity indication, indicating a larger potential market compared to diabetes [2][4]. Group 3: Competitive Landscape - Competitors are accelerating their efforts, with Novo Nordisk advancing next-generation oral GLP-1 drugs and other companies like Amgen and Pfizer developing small-molecule GLP-1 receptor agonists [3][12]. - Eli Lilly is facing increasing pricing pressure, with both Eli Lilly and Novo Nordisk planning to reduce prices for their GLP-1 drugs starting November 2025 [12]. Group 4: Future Outlook - The GLP-1 market is transitioning from a "blue ocean" to a highly competitive landscape, with projected sales of obesity drugs expected to exceed $17 billion by 2031, growing at a compound annual growth rate of 15.6% [13]. - The competition will focus on enhancing efficacy, improving delivery convenience, ensuring price accessibility, and expanding indications, indicating that the battle between Eli Lilly and Novo Nordisk is just beginning [13].

清晨的北京亦庄，北汽蓝谷工厂的智能车间里，机械臂精准舞动，每45秒就有一辆新能源汽车驶下生产线；前门大街的"非遗年货节"上，老艺人的糖画摊 位前人头攒动，年轻游客举着手机记录这份年味；京唐城际铁路的车厢内，做建材生意的张先生正翻看着合同，1小时直达唐山的通勤效率，让跨城办公 成为日常…… 2026年，"十五五"规划的开局之年，春潮涌动的京城大地上，这样的活力场景处处可见。从产业车间到消费市场，从协同战场到民生一线，北京以两会精 神为指引，锚定"地区生产总值增长5%左右"的目标，让新质生产力的引擎高速转动，让京津冀协同的脉络愈发清晰，更让高质量发展的成果浸润千家万 户。这座城市，正以稳中有进、质效双升的姿态，书写着新时代的发展答卷。 （全5022字，阅读需要18分钟） 记者｜朱开云 新质生产力支撑 "以前造芯片，核心环节得跑遍大半个中国，现在在亦庄就能完成从设计到封装的全链条配套。"北京一家半导体产业链企业负责人道出了北京高精尖产业 集群的崛起密码。这家专注高可靠通信芯片研发的企业，自2021年迁入亦庄后，收入规模增长了十几倍，背后正是北京日益完善的产业生态支撑。 （来源：半两财经） 2026年，北京将新质生产 ...

Core Insights - GLP-1 receptor agonists are being recognized for their potential independent cardiac protective effects beyond their established roles in diabetes management and weight loss, with recent research indicating a significant reduction in heart failure risk by approximately 50% [2] - The study published in the European Heart Journal demonstrates that the cardiac protective effects of GLP-1 drugs persist even when controlling for metabolic factors such as weight and blood sugar, suggesting mechanisms like improved myocardial energy metabolism and reduced inflammation [2] - This research challenges the traditional view that GLP-1 drugs are only suitable for diabetic or obese patients, providing a new theoretical basis for their use in heart failure treatment and supporting broader applications in heart failure patient populations [2] Industry Developments - Current market leaders in the GLP-1 drug segment include Eli Lilly's tirzepatide and Novo Nordisk's semaglutide, while new entrants from China, such as Innovent Biologics' mazhutide and Xianju Pharmaceutical's enoglutide, are emerging [3] - Pharmaceutical giants like Pfizer are actively developing next-generation GLP-1 drugs, with recent mid-stage trial data showing over 12% weight loss in non-diabetic patients, highlighting the competitive landscape in this therapeutic area [3]

2025年12月获纳入恒生指数成分股的信达生物（01801.HK）发布公告指，其2025年第4季和2025年全年产品收入实现强劲 增长，但其股价却并未因此而有起色，于2月5日收跌0.93%，报79.90港元，市值1,386亿港元。 全年营收破百亿 该公司预计，其2025年全年实现总产品收入约119亿元（单位人民币，下同），同比保持约45%的增长态势，我们留意到， 其2024年的产品销售收入增幅为43.64%，2025年上半年增幅为37.32%，这意味着其下半年的产品销售收入增长加快。 2025年第4季，信达生物有六款新药首次纳入2026年国家医保目录，因而计提了相应金额的一次性库存不差，即便如此，其 第4季总产品收入或仍达33亿元，同比增长60%以上，显著高于前三个季度。 值得留意的是，信达生物当前的商业化产品组合或已扩展至18款，第4季或新增达伯欣（伊匹木单抗N01注射液）和信美悦 （匹康奇拜单抗注射液）获准上市。 2025年12月29日，信达生物公告称，达伯欣（伊匹木单抗N01注射液）获国家药监局（NMPA）批准上市，根据公司提供的 资料，达伯欣或是中国第一款获批的国产抗CTLA-4单抗，也是全球第一个获 ...

Group 1: Market Overview - The global sales of GLP-1 drugs have surpassed Merck's Keytruda, with Eli Lilly's Tirzepatide generating $36.5 billion and Novo Nordisk's Semaglutide achieving $36.1 billion in 2025 [1] - The sales of Tirzepatide's weight loss indication increased by 175% year-on-year, while the diabetes indication grew by 99% [1] - The potential patient market for weight loss is significantly large, indicating a strong demand for GLP-1 drugs [1] Group 2: Company Developments - Several domestic companies, including Innovent Biologics, Jiangsu Hengrui Medicine, Tonghua Dongbao, and East China Pharmaceutical, are actively developing GLP-1 drugs to meet weight loss market demands [2] - Innovent Biologics' GLP-1 weight loss drug, Sema, has been approved for sale in China, contributing to the company's revenue growth, which is expected to exceed 10 billion yuan in 2025 [3] - Hengrui Medicine is developing HRS9531, which shows promising results in weight loss and blood sugar control, while also improving cardiovascular and renal risk factors [4] Group 3: Competitive Strategies - Companies are adopting differentiated strategies in drug development, such as creating oral formulations, extending drug half-lives, and innovating sales models [5] - Hengrui Medicine is focusing on developing a GLP-1/GIP dual receptor agonist, which aims to enhance efficacy and safety [5] - Tonghua Dongbao is also working on a GLP-1/GIP dual receptor agonist, with clinical trials progressing smoothly [5] Group 4: Research and Development Focus - Innovent Biologics is expanding its research pipeline to include long-acting, oral, and multi-target projects, aiming to provide more effective treatment options [6] - East China Pharmaceutical is developing an oral small molecule GLP-1 drug, with successful completion of all subject enrollments for its clinical phase III study in weight management [6]

本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 11 頁 v 1.2.0 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 信達生物製藥 | | | | | | 呈交日期: | 2026年2月5日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 01801 | 說明 | 普通股 | | | 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 5,000,000,000 USD 0.00001 USD 50,000 增加 / 減少 (-) 0 USD 0 本月底結存 5,000,000,000 USD 0.00001 USD 50,000 II. 已發行股份及/或庫存 ...

Core Viewpoint - The competition for the "king of drugs" title in the GLP-1 market is intensifying between Novo Nordisk and Eli Lilly, with Eli Lilly's GLP-1 drug tirzepatide significantly contributing to its revenue growth in 2025 [1][2]. Group 1: Eli Lilly's Financial Performance - Eli Lilly reported total revenue of $65.179 billion for the year 2025, a 44% increase year-over-year at constant exchange rates [1][2]. - The key driver of this growth was the GLP-1 drug tirzepatide, which generated $36.5 billion in revenue (approximately 253.4 billion RMB) [1][3]. - In Q4 2025, Eli Lilly's revenue reached $19.29 billion, a 43% year-over-year increase, with net profit soaring to $20.64 billion, up 95% [2]. Group 2: Market Dynamics and Competition - The GLP-1 market is currently dominated by Eli Lilly and Novo Nordisk, with combined revenues approaching $50 billion in 2024 [6]. - Eli Lilly's tirzepatide is positioned to capture both diabetes and obesity markets, with Zepbound's sales growth of 175% outpacing Mounjaro's growth in diabetes [1][2]. - Novo Nordisk's oral GLP-1 drug Wegovy has received FDA approval, intensifying competition in the market [7]. Group 3: Pricing and Future Outlook - Eli Lilly faces increasing pricing pressure, with both companies agreeing to lower prices for their GLP-1 drugs starting November 2025 [9]. - The global GLP-1 market is expected to see significant growth, with sales projected to exceed $17 billion by 2031, reflecting a compound annual growth rate of 15.6% from 2021 to 2031 [10]. - The competition is shifting from a "blue ocean" market to a more competitive landscape, with a focus on efficacy, convenience, pricing accessibility, and expanded indications [10].

Group 1 - GLP-1 receptor agonists are being recognized for their potential independent cardiac protective effects, beyond their established roles in diabetes and weight loss, with a recent study indicating a risk reduction for heart failure by approximately 50% through GLP-1 receptor activation [1][2] - The findings challenge the traditional view that GLP-1 drugs are only suitable for diabetic or obese patients, providing a new theoretical basis for their use in treating heart failure and supporting broader applications in heart failure patient populations [2] - Major players in the GLP-1 drug market include Eli Lilly's tirzepatide and Novo Nordisk's semaglutide, while new entrants from China, such as Innovent Biologics' mazdutide and Xian Janssen's enogratide, are emerging [2] Group 2 - Pfizer is actively developing next-generation GLP-1 drugs, with recent mid-stage trial data showing over a 12% weight reduction in non-diabetic patients, stemming from its acquisition of biotechnology company Metsera for over $10 billion [3]